Stryker said first-quarter 2026 sales growth remained at the high end of the medtech industry as it reorganized its business into two reporting segments: MedSurg and Neurotechnology, and Orthopaedics.
The company also said it combined the orthopaedic instruments portfolio with its Mako and enabling technologies businesses into a new Ortho Tech unit, bringing Mako, power tools, cutting accessories, enabling technologies and related teams under one business. Stryker said the change is intended to simplify the customer experience and speed product development.
Stryker’s products reach more than 150 million patients annually, according to the filing. Its MedSurg and Neurotechnology segment now includes surgical equipment and navigation systems, endoscopy, patient handling, emergency medical equipment, intensive care disposables, clinical communication and AI-assisted virtual care technology, vascular products, and cranial and biosurgery offerings. The Orthopaedics segment includes implants and surgical equipment for hip, knee, shoulder, ankle, trauma and extremities procedures.
The company said all historical segment information has been recast to match the new structure.
On the cost side, Stryker pointed to tariffs as a growing pressure. It said the U.S. has announced new tariffs on goods imported from dozens of countries, including China and European Union member states, and that reciprocal measures and other trade actions have followed. Stryker said tariffs are expected to increase certain product costs and could also weigh on demand and supply chains.
The company also flagged slower growth or recession, market volatility and inflation as additional risks. The market has reacted to these announcements by moving the company's shares 4.93% to a price of $331.71. For the full picture, make sure to review STRYKER CORP's 8-K report.
